inovmedИнновационная медицина КубаниInnovative Medicine of Kuban2541-9897Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 110.35401/2500-0268-2021-22-2-65-71inovmed-422Research ArticleОБЗОРЫREVIEWSРак легкого у пожилых больныхLung cancer in older patientshttps://orcid.org/0000-0003-0640-2994ХарагезовД. А.KharagezovD. A.

Харагезов Дмитрий Акимович, кандидат медицинских наук, заведующий отделением торакальной хирургии

Ростов-на-Дону

Dmitriy A. Kharagezov, Cand. Med. Sci. (Med.), Head of Department of Thoracic Surgery

Rostov-on-Don

https://orcid.org/0000-0002-6655-7632ЛазутинЮ. Н.LazutinYu. N.

Лазутин Юрий Николаевич, кандидат медицинских наук, доцент, ведущий научный сотрудник отдела торакальной хирургии

Ростов-на-Дону

Yuriy N. Lazutin, Cand. Med. Sci. (Med.), Associate Professor, Leading Researcher, Section of Thoracic Surgery

Rostov-on-Don

https://orcid.org/0000-0002-6702-7051ПыльцинС. П.PyltsinS. P.

Пыльцин Сергей Петрович, кандидат медицинских наук, врач-онколог, заместитель главного врача по медицинской части

Ростов-на-Дону

Sergey P. Pyltsin, Cand. Med. Sci. (Med.), Oncologist, Deputy Chief Physician for Medical Affairs

Rostov-on-Don

https://orcid.org/0000-0002-2589-7606МилакинА. Г.MilakinA. G.

Милакин Антон Григорьевич, врач-онколог, отделение торакальной хирургии

Ростов-на-Дону

Anton G. Milakin, Оncologist, Department of Thoracic Surgery

Rostov-on-Don

https://orcid.org/0000-0003-4513-7548СтатешныйО. Н.StateshnyO. N.

Статешный Олег Николаевич, врач-хирург, отделение торакальной хирургии

Ростов-на-Дону

Oleg N. Stateshny, Surgeon, Department of Thoracic Surgery

Rostov-on-Don

https://orcid.org/0000-0002-6655-7632ЛейманИ. А.LeymanI. A.

Лейман Игорь Александрович, кандидат медицинских наук, врач-онколог, отделение торакальной хирургии

Ростов-на-Дону

Igor A. Leyman, Cand. Med. Sci. (Med.), Oncologist, Department of Thoracic Surgery

Rostov-on-Don

https://orcid.org/0000-0002-0328-9714МирзоянЭ. А.MirzoyanE. A.

Мирзоян Эллада Арменовна, аспирант

344037, Ростов-на-Дону, ул. 14-я линия, 63

Ellada A. Mirzoyan, Postgraduate Student

63, 14th street, Rostov-on-Don, 344037

ellada.mirzoyan@yandex.ruНациональный медицинский исследовательский центрРоссияNational Medical Research Centre for OncologyRussian FederationГородская поликлиника № 14РоссияCity Polyclinic no. 14Russian Federation202130062021026571Copyright © Харагезов Д.А., Лазутин Ю.Н., Пыльцин С.П., Милакин А.Г., Статешный О.Н., Лейман И.А., Мирзоян Э.А., 20212021Харагезов Д.А., Лазутин Ю.Н., Пыльцин С.П., Милакин А.Г., Статешный О.Н., Лейман И.А., Мирзоян Э.А.Kharagezov D.A., Lazutin Y.N., Pyltsin S.P., Milakin A.G., Stateshny O.N., Leyman I.A., Mirzoyan E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.innovmedkub.ru/jour/article/view/422

Увеличение продолжительности жизни населения, как отражение успехов общественного здравоохранения, продолжает оставаться основной целью большинства социальных программ в Российской Федерации. Во всем мире существует тенденция старения населения, способствующая повышению риска развития рака легкого, который в первую очередь является заболеванием пожилых людей. Хронологический возраст сам по себе не является точным предиктором способности пациентов переносить агрессивную противоопухолевую терапию. Использование комплексной гериатрической оценки для определения оптимальной тактики лечения может снизить частоту неблагоприятных токсических явлений и неудач лечения. Сохранные пожилые больные способны переносить хирургические вмешательства, лучевую терапию и/или химиотерапию, соответствующие установленной стадии заболевания, с одинаковыми результатами как у более молодых пациентов, но с более высокой токсичностью, связанной с лечением.

Increasing life expectancy is the goal of social programs in the Russian Federation as a reflection of the success of public health. Globally, there is a trend for aging of the population, contributing to an increased risk for lung cancer developing which is primarily a disease of the elderly. Chronologic age or performance scores alone are not accurate predictors of patients’ capacity for tolerating aggressive cancer therapies. Use of a comprehensive geriatric assessment to determine treatment strategy is able to reduce toxicities and treatment failures. Safe elderly patients are often able to tolerate surgical resection, radiation, and/or chemotherapy appropriate for their tumor stage, with outcomes similar to those of younger patients, albeit with higher rates of treatment-related toxicity.

рак легкогопожилые больныескрининггериатрическая оценкахирургическое лечениестереотаксическая лучевая терапиятаргетная терапияиммунотерапияlung cancerelderly patientsscreeninggeriatric assessmentsurgical treatmentstereotactic radiation therapytargeted therapyimmunotherapyReferencesSiegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. PMID: 30620402. https://doi.org/10.3322/caac.21551Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. PMID: 30620402. https://doi.org/10.3322/caac.21551Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27. PMID: 26667886. https://doi.org/10.1158/1055-9965.EPI-15-0578Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27. PMID: 26667886. https://doi.org/10.1158/1055-9965.EPI-15-0578Presley CJ, Gross CP, Lilenbaum RC. Optimizing treatment risk and benefit for elderly patients with advanced nonsmall-cell lung cancer: the right treatment for the right patient. J Clin Oncol. 2016;34(13):1438–42. PMID: 27001591. https://doi.org/10.1200/JCO.2015.65.9599Presley CJ, Gross CP, Lilenbaum RC. Optimizing treatment risk and benefit for elderly patients with advanced nonsmall-cell lung cancer: the right treatment for the right patient. J Clin Oncol. 2016;34(13):1438–42. PMID: 27001591. https://doi.org/10.1200/JCO.2015.65.9599Venuta F, Diso D, Onorati I, Anile M, Mantovani S, Rendina EA. Lung cancer in elderly patients. J. Thorac. Dis. 2016;8(11):908–14. PMID: 27942414. PMCID: PMC5124601. https://doi.org/10.21037/jtd.2016.05.20Venuta F, Diso D, Onorati I, Anile M, Mantovani S, Rendina EA. Lung cancer in elderly patients. J. Thorac. Dis. 2016;8(11):908–14. PMID: 27942414. PMCID: PMC5124601. https://doi.org/10.21037/jtd.2016.05.20Cancer research UK. Lung cancer incidence statistics. Accessed March 29, 2016. Available online: www.cancerresearchuk.orgCancer research UK. Lung cancer incidence statistics. Accessed March 29, 2016. Available online: www.cancerresearchuk.orgSaji H, Ueno T, Nakamura H, et al. A proposal comprehensive risk scoring system for predicting postoperative complications in octagenarian patients with medically operable lung cancer: JACS1303. Eur J Cardiothorac Surg. 2018;53:835– 41. PMID: 29240884. https://doi.org/10.1093/ejcts/ezx415Saji H, Ueno T, Nakamura H, et al. A proposal comprehensive risk scoring system for predicting postoperative complications in octagenarian patients with medically operable lung cancer: JACS1303. Eur J Cardiothorac Surg. 2018;53:835– 41. PMID: 29240884. https://doi.org/10.1093/ejcts/ezx415Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2020, МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020.Malignant tumors in Russia in 2019 (morbidity and mortality). Ed. by A.D. Кaprin, V.V. Starinskii, A.O. Shachzadova Moscow 2020: MNIOI im. P.A. Gertsena – filial NMITs radiologii, 2020. (In Russ.)Peter M. Healthy Patients at Risk for Lung Cancer: Whether, How, and Who to Screen. Ch. 13 in Lung Cancer: A Practical Approach to Evidence-Based Clinical Evaluation and Management. Ed. by L. Tanque and F. Dettrbeck 2019., Elsevier Inc. p. 197–208.Peter M. Healthy Patients at Risk for Lung Cancer: Whether, How, and Who to Screen. Ch. 13 in Lung Cancer: A Practical Approach to Evidence-Based Clinical Evaluation and Management. Ed. by L. Tanque and F. Dettrbeck 2019., Elsevier Inc. p. 197–208.Dawe DE, Pond GR, Ellis PM. Assessment of referral and chemotherapy treatment patterns for elderly patients with nonsmall-cell lung cancer. Clin Lung Cancer. 2016;17(6):563–572.e2. PMID: 27374398. https://doi.org/10.1016/j.cllc.2016.05.012Dawe DE, Pond GR, Ellis PM. Assessment of referral and chemotherapy treatment patterns for elderly patients with nonsmall-cell lung cancer. Clin Lung Cancer. 2016;17(6):563–572.e2. PMID: 27374398. https://doi.org/10.1016/j.cllc.2016.05.012Sineshaw HM, Wu XC, Flanders WD, et al. Variations in receipt of curative-intent surgery for early-stage non-small cell lung cancer (NSCLC) by state. J Thorac Oncol. 2016;11(6):880–9. PMID: 26980472. https://doi.org/10.1016/j.jtho.2016.03.003Sineshaw HM, Wu XC, Flanders WD, et al. Variations in receipt of curative-intent surgery for early-stage non-small cell lung cancer (NSCLC) by state. J Thorac Oncol. 2016;11(6):880–9. PMID: 26980472. https://doi.org/10.1016/j.jtho.2016.03.003Souza RV, Basis M, Mantovani S, et al. Comparison of preoperative scores predicting outcome in elderly undergoing lung malignancies resection. J Thorac. Dis. 2020;12(12):7083– 88. PMID: 33447396. PMCID: PMC7797853. https://doi.org/10.21037/jtd-20-1622Souza RV, Basis M, Mantovani S, et al. Comparison of preoperative scores predicting outcome in elderly undergoing lung malignancies resection. J Thorac. Dis. 2020;12(12):7083– 88. PMID: 33447396. PMCID: PMC7797853. https://doi.org/10.21037/jtd-20-1622NCCN Guidelines: Older Adult Oncology. NCCN clinical practice guidelines in oncology 2016, 2. 2016. Available online: https://www.nccn.org/professionals/physiciangls/fguidelines.aspNCCN Guidelines: Older Adult Oncology. NCCN clinical practice guidelines in oncology 2016, 2. 2016. Available online: https://www.nccn.org/professionals/physiciangls/fguidelines.aspCorre R, Greillier L, Le Caer H, et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol. 2016;34(13):1476–83. PMID: 26884557. https://doi.org/10.1200/JCO.2015.63.5839Corre R, Greillier L, Le Caer H, et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol. 2016;34(13):1476–83. PMID: 26884557. https://doi.org/10.1200/JCO.2015.63.5839Gardet E, Tabutin M, Couraud S, et al. Long-term results of lung cancer surgery in octogenarians. Rev Pneumol Clin. 2016;72(1):3–9. (In French). PMID: 26725006. https://doi.org/10.1016/j.pneumo.2015.09.005Gardet E, Tabutin M, Couraud S, et al. Long-term results of lung cancer surgery in octogenarians. Rev Pneumol Clin. 2016;72(1):3–9. (In French). PMID: 26725006. https://doi.org/10.1016/j.pneumo.2015.09.005Detillon DE, Aarts MJ, Jaeger KD, Van Eijck CH, Eelco JV. Detillon DE, Aarts MJ, Jaeger KD, Van Eijck CH, Eelco JV. Video-assisted thoracic lobectomy versus stereotactic body radiotherapy for stage I nonsmall cell lung cancer in elderly patients: a propensity matched comparative analysis. Eur Respir J. 2019;53(6):1801561. PMID: 30923188. https://doi.org/10.1183/13993003.01561-2018Detillon DE, Aarts MJ, Jaeger KD, Van Eijck CH, Eelco JV. Detillon DE, Aarts MJ, Jaeger KD, Van Eijck CH, Eelco JV. Video-assisted thoracic lobectomy versus stereotactic body radiotherapy for stage I nonsmall cell lung cancer in elderly patients: a propensity matched comparative analysis. Eur Respir J. 2019;53(6):1801561. PMID: 30923188. https://doi.org/10.1183/13993003.01561-2018Pagès P-B., Mariet A-S, Madelaine L, Cottenet J, et al. Impact of video-assisted thoracic surgery approach on postoperative mortality after lobectomy in octogenarians. J Thorac Cardiovasc Surg. 2019;157(4):1660–67. PMID: 30711277. https://doi.org/10.1016/j.jtcvs.2018.11.098Pagès P-B., Mariet A-S, Madelaine L, Cottenet J, et al. Impact of video-assisted thoracic surgery approach on postoperative mortality after lobectomy in octogenarians. J Thorac Cardiovasc Surg. 2019;157(4):1660–67. PMID: 30711277. https://doi.org/10.1016/j.jtcvs.2018.11.098Drevet G, Maury J-M, Ginoux M, Tronc F. Morbimortalité de la résection pulmonaire pour cancer par chirurgie vidéo-assistée chez l’octogénaire. Rev Mal Respir. 2020;37(4):293– 298. (In French). PMID: 32273117. https://doi.org/10.1016/j.rmr.2020.01.007Drevet G, Maury J-M, Ginoux M, Tronc F. Morbimortalité de la résection pulmonaire pour cancer par chirurgie vidéo-assistée chez l’octogénaire. Rev Mal Respir. 2020;37(4):293– 298. (In French). PMID: 32273117. https://doi.org/10.1016/j.rmr.2020.01.007Bravo-Iniguez CE, Armstrong KW, Cooper Z, et al. Thirtyday mortality after lobectomy in elderly patients eligible for lung cancer screening. Ann Thorac Surg. 2016;101(2):541–6. PMID: 26603020. https://doi.org/10.1016/j.athoracsur.2015.08.067Bravo-Iniguez CE, Armstrong KW, Cooper Z, et al. Thirtyday mortality after lobectomy in elderly patients eligible for lung cancer screening. Ann Thorac Surg. 2016;101(2):541–6. PMID: 26603020. https://doi.org/10.1016/j.athoracsur.2015.08.067Smith CB, Kale M, Mhango G, et al. Comparative outcomes of elderly stage I lung cancer patients treated with segmentectomy via video-assisted thoracoscopic surgery versus open resection. J Thorac Oncol. 2014;9(3):383–9. PMID: 24495998. https://doi.org/10.1097/JTO.0000000000000083Smith CB, Kale M, Mhango G, et al. Comparative outcomes of elderly stage I lung cancer patients treated with segmentectomy via video-assisted thoracoscopic surgery versus open resection. J Thorac Oncol. 2014;9(3):383–9. PMID: 24495998. https://doi.org/10.1097/JTO.0000000000000083Razi SS, John MM, Sainathan S, et al. Sublobar resection is equivalent to lobectomy for T1a non-small cell lung cancer in the elderly: a surveillance, epidemiology, and end results database analysis. J Surg Res. 2016;200(2):683–9. PMID: 26490227. https://doi.org/10.1016/j.jss.2015.08.045Razi SS, John MM, Sainathan S, et al. Sublobar resection is equivalent to lobectomy for T1a non-small cell lung cancer in the elderly: a surveillance, epidemiology, and end results database analysis. J Surg Res. 2016;200(2):683–9. PMID: 26490227. https://doi.org/10.1016/j.jss.2015.08.045Zhang Y, Yuan C, Zhang Y, et al. Survival following segmentectomy or lobectomy in elderly patients with early-stage lung cancer. Oncotarget. 2016;7(14):19081–6. PMID: 26934652 PMCID: PMC4951354. https://doi.org/10.18632/oncotarget.7704Zhang Y, Yuan C, Zhang Y, et al. Survival following segmentectomy or lobectomy in elderly patients with early-stage lung cancer. Oncotarget. 2016;7(14):19081–6. PMID: 26934652 PMCID: PMC4951354. https://doi.org/10.18632/oncotarget.7704Altorki NK, Wang X, Wigle D, et al. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respir Med. 2018;6(12):915–924. PMID: 30442588. PMCID: PMC6396275. https://doi.org/10.1016/S2213-2600(18)30411-9Altorki NK, Wang X, Wigle D, et al. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respir Med. 2018;6(12):915–924. PMID: 30442588. PMCID: PMC6396275. https://doi.org/10.1016/S2213-2600(18)30411-9Kato A, Yokomise H. [Perioperative Management for Lung Cancer in the Elderly Over 75 Years Old.] Kyobu Geka. 2020 Sep;73(10):812-818 (In Jap.).Kato A, Yokomise H. [Perioperative Management for Lung Cancer in the Elderly Over 75 Years Old.] Kyobu Geka. 2020 Sep;73(10):812-818 (In Jap.).National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small cell lung cancer. Version 1.2020-November 6, 2019. Available online: www.nccn.org/professionals/physiciangls/pdf/nscl.pdf.National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small cell lung cancer. Version 1.2020-November 6, 2019. Available online: www.nccn.org/professionals/physiciangls/pdf/nscl.pdf.Nanda RH, Liu Y, Gillespie TW, et al. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: a National cancer data base analysis. Cancer. 2015;121(23): 4222–30. PMID: 26348268. https://doi.org/10.1002/cncr.29640Nanda RH, Liu Y, Gillespie TW, et al. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: a National cancer data base analysis. Cancer. 2015;121(23): 4222–30. PMID: 26348268. https://doi.org/10.1002/cncr.29640Paul S, Lee PC, Mao J, et al. Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis. BMJ. 2016;354:i3570. PMID: 27400862. PMCID: PMC4937638. https://doi.org/10.1136/bmj.i3570Paul S, Lee PC, Mao J, et al. Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis. BMJ. 2016;354:i3570. PMID: 27400862. PMCID: PMC4937638. https://doi.org/10.1136/bmj.i3570Dupuy DE, Fernando HC, Hillman S, et al. Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial. Cancer. 2015;121(19):3491–8. PMID:26096694. PMCID:PMC4578219. https://doi.org/10.1002/cncr.29507Dupuy DE, Fernando HC, Hillman S, et al. Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial. Cancer. 2015;121(19):3491–8. PMID:26096694. PMCID:PMC4578219. https://doi.org/10.1002/cncr.29507Ganti AK, Williams CD, Gajra A, et al. Effect of age on the efficacy of adjuvant chemotherapy for resected non–small cell lung cancer. Cancer. 2015;121(15):2578–85. PMID: 25873330. https://doi.org/10.1002/cncr.29360Ganti AK, Williams CD, Gajra A, et al. Effect of age on the efficacy of adjuvant chemotherapy for resected non–small cell lung cancer. Cancer. 2015;121(15):2578–85. PMID: 25873330. https://doi.org/10.1002/cncr.29360Dawe DE, Christiansen D, Swaminath A, et al. Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: a systematic review and meta-analysis. Lung Cancer. 2016;99:180–5. PMID: 27565937. https://doi.org/10.1016/j.lungcan.2016.07.016Dawe DE, Christiansen D, Swaminath A, et al. Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: a systematic review and meta-analysis. Lung Cancer. 2016;99:180–5. PMID: 27565937. https://doi.org/10.1016/j.lungcan.2016.07.016Sacher AG, Dahlberg SE, Heng J, et al. Association between younger age and targetable genomic alterations and prognosis in non–small-cell lung cancer. JAMA Oncol. 2016;2(3):313–20. PMID: 26720421. PMCID: PMC4819418. https://doi.org/10.1001/jamaoncol.2015.4482Sacher AG, Dahlberg SE, Heng J, et al. Association between younger age and targetable genomic alterations and prognosis in non–small-cell lung cancer. JAMA Oncol. 2016;2(3):313–20. PMID: 26720421. PMCID: PMC4819418. https://doi.org/10.1001/jamaoncol.2015.4482Awad MM, Oxnard GR, Jackman DM, et al. MET Exon 14 mutations in non–smallcell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34(7):721–30. PMID: 26729443. https://doi.org/10.1200/JCO.2015.63.4600Awad MM, Oxnard GR, Jackman DM, et al. MET Exon 14 mutations in non–smallcell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34(7):721–30. PMID: 26729443. https://doi.org/10.1200/JCO.2015.63.4600Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415–26. PMID: 26777916. https://doi.org/10.1016/S0140-6736(16)00004-0Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415–26. PMID: 26777916. https://doi.org/10.1016/S0140-6736(16)00004-0McLoughlin EM, Gentzler RD. Epidermal Growth Factor Receptor Mutations. Thorac. Surg. Clin. 2020;30:127–136. PMID: 32327171. https://doi.org/10.1016/j.thorsurg.2020.01.008McLoughlin EM, Gentzler RD. Epidermal Growth Factor Receptor Mutations. Thorac. Surg. Clin. 2020;30:127–136. PMID: 32327171. https://doi.org/10.1016/j.thorsurg.2020.01.008Reckamp KL, Molecular Targets Beyond the Big 3. Thorac. Surg Clin. 2020;30:157–164. PMID: 32327174. https://doi.org/10.1016/j.thorsurg.2020.01.004Reckamp KL, Molecular Targets Beyond the Big 3. Thorac. Surg Clin. 2020;30:157–164. PMID: 32327174. https://doi.org/10.1016/j.thorsurg.2020.01.004Hsu M, Naidoo J. Principles of Immunotherapy in NonSmall Cell Lung Cancer. Thorac Surg Clin. 2020;30:187–198. PMID: 32327177 https://doi.org/10.1016/j.thorsurg.2020.01.009Hsu M, Naidoo J. Principles of Immunotherapy in NonSmall Cell Lung Cancer. Thorac Surg Clin. 2020;30:187–198. PMID: 32327177 https://doi.org/10.1016/j.thorsurg.2020.01.009Broderick SR. Adjuvant and Neoadjuvant Immunotherapy in Non–small Cell Lung Cancer. Thorac Surg Clin. 2020;30(2):215–220. PMID: 32327180. https://doi.org/10.1016/j.thorsurg.2020.01.001Broderick SR. Adjuvant and Neoadjuvant Immunotherapy in Non–small Cell Lung Cancer. Thorac Surg Clin. 2020;30(2):215–220. PMID: 32327180. https://doi.org/10.1016/j.thorsurg.2020.01.001Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883–95. PMID: 27269741. https://doi.org/10.1016/S1470-2045(16)30098-5Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883–95. PMID: 27269741. https://doi.org/10.1016/S1470-2045(16)30098-5

The authors declare that there are no conflicts of interest present.